Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hatice Bozkurt Yavuz, Mehmet Akif Bildirici, Hüseyin Yaman, Süleyman Caner Karahan, Yüksel Aliyazıcıoğlu & Asım Örem. (2021) Reference change value and measurement uncertainty in the evaluation of tumor markers. Scandinavian Journal of Clinical and Laboratory Investigation 81:7, pages 601-605.
Read now
Read now
Simon P Langdon, Charlie Gourley, Hani Gabra & Barbara Stanley. (2017) Endocrine therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy 17:2, pages 109-117.
Read now
Read now
Per Hyltoft Petersen. (2012) Critical comments on ‘Significance of a change between two consecutive measured values’. Scandinavian Journal of Clinical and Laboratory Investigation 72:2, pages 173-174.
Read now
Read now
K Stephen Suh, Sang W Park, Angelica Castro, Hiren Patel, Patrick Blake, Michael Liang & Andre Goy. (2010) Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Review of Molecular Diagnostics 10:8, pages 1069-1083.
Read now
Read now
Articles from other publishers (23)
Georgia Zachou, Fatima El-Khouly & James Dilley. (2023) Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2023:8.
Crossref
Crossref
Zhongyu Wang, Yake Huang, Ling Long, Li Zhou, Yan Huang, Lei Gan, Aimin Pu, Sufen Li & Rongkai Xie. (2021) Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression. Journal of Ovarian Research 14:1.
Crossref
Crossref
Anette Stolberg Kargo, Pernille Tine Jensen, Kristina Lindemann, Niels Henrik Hjøllund, Gabor Istvan Liposits, Nicoline Raaschou-Jensen, Bettina Mølri Knudsen, Sören Möller, Dorte Gilså Hansen & Karina Dahl Steffensen. (2021) Association of patient-reported outcomes and ovarian cancer recurrence. International Journal of Gynecologic Cancer 31:9, pages 1248-1259.
Crossref
Crossref
Meshach Asare-Werehene, Laudine Communal, Euridice Carmona, Tien Le, Diane Provencher, Anne-Marie Mes-Masson & Benjamin K. Tsang. (2019) Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer. Scientific Reports 9:1.
Crossref
Crossref
George Georgiadis, Charalampos Belantis, Charalampos Mamoulakis, John Tsiaoussis, Wallace A. Hayes & Aristidis M. Tsatsakis. 2019. Biomarkers in Toxicology. Biomarkers in Toxicology
855
867
.
Suher O Abu Hassan, Dorte L Nielsen, Malgorzata K Tuxen, Per H Petersen & György Sölétormos. (2017) Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period. Future Science OA 3:3, pages FSO216.
Crossref
Crossref
Ayala Tamir, Anju Gangadharan, Sakshi Balwani, Takemi Tanaka, Ushma Patel, Ahmed Hassan, Stephanie Benke, Agnieszka Agas, Joseph D’Agostino, Dayoung Shin, Sunghoon Yoon, Andre Goy, Andrew Pecora & K. Stephen Suh. (2016) The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer. Journal of Ovarian Research 9:1.
Crossref
Crossref
KARINA DAHL STEFFENSEN, MARIANNE WALDSTRØM, IVAN BRANDSLUND, BENTE LUND, SARAH MEJER SØRENSEN, MAX PETZOLD & ANDERS JAKOBSEN. (2016) Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncology Letters 11:6, pages 3967-3974.
Crossref
Crossref
György Sölétormos, Michael J. Duffy, Suher Othman Abu Hassan, René H.M. Verheijen, Bengt Tholander, Robert C. BastJrJr, Katja N. Gaarenstroom, Catharine M. Sturgeon, Johannes M. Bonfrer, Per Hyltoft Petersen, Hugo Troonen, Gian CarloTorre, Jan Kanty Kulpa, Malgorzata K. Tuxen & Raphael Molina. (2016) Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer 26:1, pages 43-51.
Crossref
Crossref
Suher Othman Abu Hassan, Per Hyltoft Petersen, Flemming Lund, Dorte L Nielsen, Malgorzata K Tuxen & György Sölétormos. (2015) Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation. Biomarkers in Medicine 9:9, pages 911-922.
Crossref
Crossref
Ayala Tamir, Ushma Jag, Sreeja Sarojini, Craig Schindewolf, Takemi Tanaka, Rajendra Gharbaran, Hiren Patel, Anil Sood, Wei Hu, Ruzeen Patwa, Patrick Blake, Polina Chirina, Jin Oh Jeong, Heejin Lim, Andre Goy, Andrew Pecora & K Stephen Suh. (2014) Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. Journal of Ovarian Research 7:1.
Crossref
Crossref
Tilean Clarke, Khadra Galaal, Andrew Bryant & Raj Naik. (2014) Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2018:9.
Crossref
Crossref
Brian M. Nolen & Anna E. Lokshin. 2014. Biomarkers in Toxicology. Biomarkers in Toxicology
759
770
.
Michèl Schummer, Charles Drescher, Robin Forrest, Shirley Gough, Jason Thorpe, Ingegerd Hellström, Karl Erik Hellström & Nicole Urban. (2012) Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecologic Oncology 125:1, pages 65-69.
Crossref
Crossref
Fiona Kew, Khadra Galaal, Andrew Bryant & Raj Naik. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Garo Z. Harmandayan, Feng Gao, David G. Mutch, Katherine S. Virgo, Randall K. Gibb & Frank E. Johnson. (2011) Ovarian cancer patient surveillance after curative-intent initial treatment. Gynecologic Oncology 120:2, pages 205-208.
Crossref
Crossref
Jean A. Hurteau, Mark F. Brady, Kathleen M. Darcy, William P. McGuire, Pamela Edmonds, Michael L. Pearl, Iouri Ivanov, Krishnansu S. Tewari, Robert S. Mannel, Kristine Zanotti & Doris M. Benbrook. (2010) Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic Oncology 119:3, pages 444-450.
Crossref
Crossref
Amer K. Karam & Beth Y. Karlan. (2010) Ovarian cancer: the duplicity of CA125 measurement. Nature Reviews Clinical Oncology 7:6, pages 335-339.
Crossref
Crossref
Srdjan Djurdjevic, Sanja Stojanovic, Marijana Basta-Nikolic & Marko Maksimovic. (2010) Rational application of tumor marker CA 125 in gynecological oncology. Medicinski pregled 63:3-4, pages 195-199.
Crossref
Crossref
Robert L. Coleman, Alan Gordon, James Barter, Steven Sun, Wayne Rackoff & Thomas J. Herzog. (2007) Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients. The Oncologist 12:1, pages 72-78.
Crossref
Crossref
J. KLOSTERGAARD, E. AUZENNE, S. GHOSH, D. FARQUHAR, B. RIVERA & R.E. PRICE. (2006) Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response. International Journal of Gynecological Cancer 16:S1, pages 111-117.
Crossref
Crossref
M.J. DUFFY, J.M. BONFRER, J. KULPA, G.J.S. RUSTIN, G. SOLETORMOS, G.C. TORRE, M.K. TUXEN & M. ZWIRNER. (2005) CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. International Journal of Gynecological Cancer 15:5, pages 679-691.
Crossref
Crossref
Curtis Balch, Tim H.-M. Huang, Robert Brown & Kenneth P. Nephew. (2004) The epigenetics of ovarian cancer drug resistance and resensitization. American Journal of Obstetrics and Gynecology 191:5, pages 1552-1572.
Crossref
Crossref